• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

CellRapeutics™ CART Development Service for Fibrotic Diseases

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Fibrosis and Fibrotic Diseases

Fibrosis refers to the development of fibrous connective tissue as a reparative response to injury or damage. The process involves the activation of certain cells (like fibroblasts or myofibroblasts) that produce and deposit extracellular matrix (ECM) components in the affected tissue. This matrix deposition exceeds the normal rate of ECM turnover and degradation, leading to an excess accumulation of fibrous tissue. Normally, the formation of fibrous tissue is critical for healing. However, when fibrosis becomes chronic or uncontrollable, it can lead to serious health problems, including a group of conditions known as fibrotic diseases.

Fibrotic diseases can affect almost any part of the body, including the lungs, liver, kidneys, heart, and skin among others. Some well-known fibrotic diseases include pulmonary fibrosis, cardiac fibrosis, cystic fibrosis, liver cirrhosis, and systemic sclerosis. Creative Biolabs is pleased to launch CAR-T development services, contributing to the advancement in treating fibrotic diseases. Our state-of-the-art facilities and experienced personnel ensure that your CAR-T cells are produced following the highest quality and regulatory standards.

Fig.1 The major mechanisms of fibrosis.¹

One-stop CAR-T Platform for Fibrotic Diseases

At Creative Biolabs, we are committed to offering CAR-T development services for fibrotic diseases. Our highly experienced team has the expertise to provide a tailored CAR-T therapy solution. They are skilled at designing and constructing CARs, CAR-T gene packaging and delivery, in vitro validation of CAR-T cells, CAR-T expansion, and CAR-T characterization, always ensuring we meet the highest standards for safety and efficacy. Our experts provide step-by-step guidance throughout the process, helping to interpret results and make data-driven decisions.

We utilize a sophisticated approach to identify relevant antigen targets and design a CAR to target the specific antigen. The engineered T cells are designed to target specific proteins found at high levels in fibrotic cardiac tissue, such as the fibroblast activation protein (FAP). We provide various CAR gene delivery approaches including viral and non-viral based transfection. We also synthesize IVT mRNA for in vivo CAR-T cell engineering via LNP delivery. Once these CAR-T cells recognize these proteins, they stimulate an immune response against the fibroblasts, alleviating the process of fibrosis.

Applications

CAR-T therapy has the potential for various fibrotic diseases. At Creative Biolabs, our scientists are focused on the development of innovative and advanced therapeutic strategies for the following fibrotic diseases:

• Pulmonary fibrosis
• Cardiac fibrosis
• Cystic fibrosis
• Liver cirrhosis
• Systemic sclerosis

Features

• Our CAR-T services cover a wide range of fibrotic diseases.
• We offer tailor-made CAR-T development services to meet the specific needs of your research in fibrotic diseases.
• We offer extensive technical and customer support from the initial stage of development, through to the clinical research phase.
• We ensure a rapid turnaround time without compromising on quality.

Partner with us to accelerate your CAR-T cell therapy programs for fibrotic diseases!

Reference

1. Antar, et al.; "Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation." International Journal of Molecular Sciences 24.4 (2023): 4004.